Drug treatment of toxoplasmic encephalitis in acquired immunodeficiency syndrome.
Toxoplasma gondii is a ubiquitous parasite, which causes several serious diseases. Until the AIDS pandemic, toxoplasmic encephalitis was largely confined to the pharmacologically immune-suppressed and to cases of congenital transmission. T gondii is now one of the more commonly encountered opportunistic pathogens of advanced AIDS.
Winstanley
P
P
Department of Pharmacology and Therapeutics, University of Liverpool, UK.
D017088:AIDS-Related Opportunistic Infections / Q000175:diagnosis / Q000188:drug therapy*; D053626:Atovaquone; D002981:Clindamycin / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003049:Coccidiostats / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D009285:Naphthoquinones / Q000494:pharmacology; D011739:Pyrimethamine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013411:Sulfadiazine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016781:Toxoplasmosis, Cerebral / Q000175:diagnosis / Q000188:drug therapy*
D003049:Coccidiostats; D009285:Naphthoquinones; D013411:Sulfadiazine; D002981:Clindamycin; D053626:Atovaquone; D011739:Pyrimethamine